GO Main Menu Go Main Contents Go Bottom Menu

Pop-up layer

Notice to shareholders

■ Our response to our shareholders’ inquiries about U.S. President Biden’s “Executive Order to launch a National Biotechnology and Biomanufacturing Initiative” are as follows:


■ After a thorough review of the Executive Order, we view it would have little, if any, impact on Celltrion Group. 


■ Celltrion Group brings mostly in-house developed antibody products to market, and the CMO business takes an insignificant portion of the business, unlike the concerns of some experts and media. 


■ Any products launched in the US after 2023 will be directly sold by a U.S. legal entity of Celltrion Healthcare. 


■ While Celltrion Group has secured several manufacturing sites home and abroad for the production of API and finished products, Celltrion Group will be actively considering options for obtaining manufacturing sites in the US if it is deemed to be beneficial to Celltrion Group after a thorough review of policies including incentives on investments in the US.

bg_01_1.jpg
bg_01_2.jpg
192315510900-433db52a-a7a0-4c0b-b096-e9468ceef9aa.jpg

Celltrion Healthcare

We have been contributing to the improvement of patient welfare and access to healthcare by offering innovative biologics to the world.

BUSINESSWe are exerting efforts to achieve sustainable growth.

Celltrion Healthcare will shape a healthier and happier future for humanity by offering high-quality biologics.

Celltrion Healthcare offers biologics to about 110 countries, along with more than 30 global partners around the world. With hands-on experience and knowledge accumulated through years of working in the advanced pharmaceutical markets of the United States and Europe, Celltrion Healthcare has been securing distribution channels and providing patients with biosimilars at affordable prices.

PRODUCTS

Remsima®

Remsima® is a biosimilar infliximab approved by the European Medicines Agency (EMA) in August 2013 and the U.S. Food and Drug Administration (FDA) in April 2016. It is indicated for the treatment of Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), and Psoriasis.

Click here for details

main product Remsima The world’s first biosimilar
monoclonal antibody

PRODUCTS

Truxima®

Truxima® is a biosimilar rituximab approved by the European Medicines Agency (EMA) in February 2017 and the U.S. Food and Drug Administration (FDA) in November 2018. It is indicated for the treatment of Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), and Rheumatoid Arthritis(RA).

Click here for details

main product Truxima The world’s first biosimilar
anticancer antibody

PRODUCTS

Herzuma®

Herzuma® is a biosimilar trastuzumab approved by the European Medicines Agency (EMA) in February 2018 and the U.S. Food and Drug Administration (FDA) in December 2018. It is indicated for the treatment of HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), and Metastatic Gastric Cancer(MGC).

Click here for details

main product Herzuma Biosimilar anticancer antibody

PRODUCTS

Remsima®SC

Remsima®SC is a SC formulation of biosimilar infliximab approved by the European Medicines Agency (EMA) in November 2019. It is indicated for the treatment of Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients.

Click here for details

램시마SC 제품이미지 The world's first subcutaneous
infliximab biosimilar

GLOBAL NETWORKS

Global biologics
leading company

Celltrion Healthcare has become the world’s leading company that specializes in biologics by offering high-quality biosimilars to about 110 countries, with the ultimate goal of promoting the welfare of humanity.

Click here for details